ICR calls for wider gene testing in ovarian cancer after approval of olaparib earlier in treatment for women with BRCA mutations 26 Jul 2019
The ICR responds to decision by NICE not to recommend abiraterone as first-line treatment for advanced prostate cancer 06 Jun 2018
The ICR responds to the FDA approval of olaparib for women with BRCA-mutant advanced breast cancer 12 Jan 2018
European Medicines Agency approves abiraterone combined with hormone therapy as first-line treatment for advanced prostate cancer 22 Nov 2017
ICR responds to NICE approval of new breakthrough drugs on the NHS for women with advanced breast cancer 16 Nov 2017